<?xml version='1.0' encoding='utf-8'?>
<document id="23552887"><sentence text="Potential protective effect of sunitinib after administration of diclofenac: biochemical and histopathological drug-drug interaction assessment in a mouse model."><entity charOffset="31-40" id="DDI-PubMed.23552887.s1.e0" text="sunitinib" /><entity charOffset="65-75" id="DDI-PubMed.23552887.s1.e1" text="diclofenac" /><pair ddi="false" e1="DDI-PubMed.23552887.s1.e0" e2="DDI-PubMed.23552887.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23552887.s1.e0" e2="DDI-PubMed.23552887.s1.e1" /></sentence><sentence text="Sunitinib is a tyrosine kinase inhibitor for GIST and advanced renal cell carcinoma"><entity charOffset="0-9" id="DDI-PubMed.23552887.s2.e0" text="Sunitinib" /><entity charOffset="15-23" id="DDI-PubMed.23552887.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.23552887.s2.e0" e2="DDI-PubMed.23552887.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23552887.s2.e0" e2="DDI-PubMed.23552887.s2.e1" /></sentence><sentence text=" Diclofenac is used in cancer pain management"><entity charOffset="1-11" id="DDI-PubMed.23552887.s3.e0" text="Diclofenac" /></sentence><sentence text=" Coadministration may mediate P450 toxicity" /><sentence text=" We evaluate their interaction, assessing biomarkers ALT, AST, BUN, creatinine, and histopathological changes in the liver, kidney, heart, brain, and spleen"><entity charOffset="68-78" id="DDI-PubMed.23552887.s5.e0" text="creatinine" /></sentence><sentence text=" ICR mice (male, n = 6 per group/dose) were administered saline (group A) or 30 mg/kg diclofenac ip (group B), or sunitinib po at 25, 50, 80, 100, 140 mg/kg (group C) or combination of diclofenac (30 mg/kg, ip) and sunitinib (25, 50, 80, 100, 140 mg/kg po)"><entity charOffset="114-123" id="DDI-PubMed.23552887.s6.e0" text="sunitinib" /><entity charOffset="185-195" id="DDI-PubMed.23552887.s6.e1" text="diclofenac" /><entity charOffset="215-224" id="DDI-PubMed.23552887.s6.e2" text="sunitinib" /><pair ddi="false" e1="DDI-PubMed.23552887.s6.e0" e2="DDI-PubMed.23552887.s6.e0" /><pair ddi="false" e1="DDI-PubMed.23552887.s6.e0" e2="DDI-PubMed.23552887.s6.e1" /><pair ddi="false" e1="DDI-PubMed.23552887.s6.e0" e2="DDI-PubMed.23552887.s6.e2" /><pair ddi="false" e1="DDI-PubMed.23552887.s6.e1" e2="DDI-PubMed.23552887.s6.e1" /><pair ddi="false" e1="DDI-PubMed.23552887.s6.e1" e2="DDI-PubMed.23552887.s6.e2" /></sentence><sentence text=" Diclofenac was administered 15 min before sunitinib, mice were euthanized 4 h post-sunitinib dose, and biomarkers and tissue histopathology were assessed"><entity charOffset="1-11" id="DDI-PubMed.23552887.s7.e0" text="Diclofenac" /><entity charOffset="43-52" id="DDI-PubMed.23552887.s7.e1" text="sunitinib" /><pair ddi="false" e1="DDI-PubMed.23552887.s7.e0" e2="DDI-PubMed.23552887.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23552887.s7.e0" e2="DDI-PubMed.23552887.s7.e1" /></sentence><sentence text=" AST was 92" /><sentence text="2 ± 8" /><sentence text="0 U/L in group A and 159" /><sentence text="7 ± 14" /><sentence text="6 U/L in group B (p &lt; 0" /><sentence text="05); in group C, it the range was 105" /><sentence text="1-152" /><sentence text="6 U/L, and in group D, it was 156" /><sentence text="0-209" /><sentence text="5 U/L (p &lt; 0" /><sentence text="05)" /><sentence text=" ALT was 48" /><sentence text="9 ± 1" /><sentence text="6 U/L (group A), 95" /><sentence text="1 ± 4" /><sentence text="5 U/L (p &lt; 0" /><sentence text="05) in group B, and 50" /><sentence text="5-77" /><sentence text="5 U/L in group C and 82" /><sentence text="3-115" /><sentence text="6 U/L after coadministration (p &lt; 0" /><sentence text="05)" /><sentence text=" Renal function biomarker BUN was 16" /><sentence text="3 ± 0" /><sentence text="6 mg/dl (group A) and increased to 29" /><sentence text="9 ± 2" /><sentence text="6 mg/dl in group B (p &lt; 0" /><sentence text="05) and it the range was 19" /><sentence text="1-33" /><sentence text="3 mg/dl (p &lt; 0" /><sentence text="05) and 26" /><sentence text="9-40" /><sentence text="8 mg/dl in groups C and D, respectively" /><sentence text=" Creatinine was 5"><entity charOffset="1-11" id="DDI-PubMed.23552887.s41.e0" text="Creatinine" /></sentence><sentence text="9 pmol/ml in group A; 6" /><sentence text="2 pmol/ml in group B (p &lt; 0" /><sentence text="01), and the range was 6" /><sentence text="0-6" /><sentence text="2 and 6" /><sentence text="2-6" /><sentence text="4 pmol/ml in groups C and D, respectively (p &lt; 0" /><sentence text="05 for D)" /><sentence text=" Histopathological assessment (vascular and inflammation damages) showed toxicity in group B (p &lt; 0" /><sentence text="05) and mild toxicity in group C" /><sentence text=" Damage was significantly lesser in group D than group B (p &lt; 0" /><sentence text="05)" /><sentence text=" Spleen only showed toxicity after coadministration" /><sentence text=" These results suggest vascular and inflammation protective effects of sunitinib, not shown after biomarker analysis"><entity charOffset="71-80" id="DDI-PubMed.23552887.s55.e0" text="sunitinib" /></sentence><sentence text="" /></document>